Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
|Articles|October 7, 2022
News Roundup: October 3 to October 7
Author(s)Miranda Hester
Your weekly roundup of the latest news from Drug Topics®.
Advertisement
Preparing to Counsel Patients on OTC Hearing Aids
OTC hearing aids will soon be available, but this access also comes with questions about counseling and ensuring safety.
Looking to the Southern Hemisphere for Clues on the 2022-2023 Flu Season
Does the severe flu season in the southern hemisphere hint at a tough season for the north?
Embrace Artificial Intelligence in the Pharmacy
As technology advances in all areas of life, it is no surprise that technology is becoming more prevalent in independent pharmacy.
Motivate, Incentivize Your Team After the “Great Resignation”
It’s more important than ever to keep your team motivated and incentivized.
Self-Management Education Key in Managing Hyperglycemia in Diabetes
Evidence suggests it improves outcomes and reduces hospitalizations.
Advertisement
Related to this article
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Cheri Schmit explains how pharmacists' roles are growing beyond dispensing into prevention, test-and-treat, and artificial intelligence-supported patient care.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
3
FAQ: Scaling Pharmacy Services Through GLP-1 Care | NCPA 2026
4
Pharmacists Step Up on Test-To-Treat This American Pharmacist Month
5